Paper
RSC Advances
3.6 Cytotoxicity studies
Acknowledgements
The cells were seeded in 96-well plates (Nunc) at the density
of 5000 cells/well (MCF-7 and PANC-1) and 4000 cells/well
(NHDF) and incubated at 37 C for 24 h. The assay was per-
formed following a 72 h incubation with varying concentra-
tions of the compounds that were being tested. Then, 20 mL of
CellTiter 96®AQueous One Solution-MTS (Promega) was
added to each well (with 100 mL DMEM without phenol red)
This work was supported by the Ministry of Science and
Higher Education, Poland (Diamentowy Grant number 0215/
DIA/2015/44 (D. Z.)) and the National Science Centre of
Poland Projects: ETIUDA 6 2018/28/T/ST5/00005 (D. Z.);
PRELUDIUM 12 2016/23/N/NZ7/00351 (K. M.). Calculations
have been carried out using resources provided by Wroclaw
Centre for Networking and Supercomputing (http://wcss.pl),
grant no. 18.
ꢀ
ꢀ
followed by incubation for further 1 h at 37 C. The optical
densities of the samples were analyzed at 490 nm using
a multi-plate reader (Synergy 4, Bio Tek). The results were
expressed as a percentage of the control and calculated as the
inhibitory concentration (IC50) values (using GraphPad Prism
7). Each individual compound was tested in triplicate in
a single experiment with each experiment being repeated
three or four times.
Notes and references
¨
1 A. Wild, A. Winter, F. Schlutter and U. S. Schubert, Chem. Soc.
Rev., 2011, 40, 1459–1511.
2 C.-F. Zhang, H.-X. Huang, B. Liu, M. Chen and D.-J. Qian, J.
Lumin., 2008, 128, 469–475.
3 D. Saccone, C. Magistris, N. Barbero, P. Quagliotto, C. Barolo
and G. Viscardi, Materials, 2016, 9, 137.
4 Conclusions
4 D. Zych, A. Slodek, M. Matussek, M. Filapek, G. Szafraniec-
Herein, we presented a synthesis method and comprehensive
characterization of the derivatives 3A1–3A7 of 40-(1,2,3-tri-
azol-4-yl)phenyl-2,20:60,200-terpyridine with various (hetero)
aryl substituents. All compounds were obtained by Cu(I)-
catalysed 1,3-dipolar cycloaddition reactions with yields
between 21 and 42%. The target compounds have high
thermal stability with a temperature of 5% sample weight
´
Gorol, S. Maslanka, S. Krompiec, S. Kotowicz, E. Schab-
´
Balcerzak, K. Smolarek, S. Mackowski, M. Olejnik and
W. Danikiewicz, Dyes Pigm., 2017, 146, 331–343.
5 R. Lakshmanan, N. C. Shivaprakash and S. S. Nair, J. Lumin.,
2015, 168, 145–150.
6 E. I. Ikitimur-Armutak, K. Sonmez, K. Akgun-Dar,
G. Sennazli, A. Kapucu, F. Yigit, V. T. Yilmaz and
E. Ulukaya, Anticancer Res., 2015, 35, 1491–1497.
7 A. M. Arundhoti Mandal, A. Maity, S. Bag, P. Bhattacharya,
A. K. Das and A. Basak, RSC Adv., 2017, 7, 7163–7169.
8 A. Winter, G. R. Newkome and U. S. Schubert, ChemCatChem,
2011, 3, 1384–1406.
ꢀ
loss above 315 C. The compounds 3A1–3A7 have displayed
almost identical absorption maxima (274–278 nm) with an
exception for 3A7 that exhibits an additional band at 330 nm.
All the obtained compounds exhibit uorescence in the range
of 360–442 nm with quantum yields in the range of 7–41%
and effective lifetime values in the range from 0.41 to 4.21 ns.
From the electrochemical point of view, 3A6 with the diben-
zothiophene substituent has lowest oxidation potential,
similar to 3A7 that contains the 2,20-bithiophene unit.
Derivatives with the phenyl or pyridine ring undergo oxida-
tion at highest potentials. The observed differences are in
agreement with the results of the theoretical calculations,
which show disparities of contribution in the creation of
particular orbitals. Moreover, the preliminary tests of the
anticancer activity of the described terpyridine derivatives
3A1–3A7 conducted on two cancer cell lines, i.e. breast (MCF-
7) and pancreatic (PANC-1), show that the group of studied
compounds also has medicinal value, with comparable IC50
values. The most active derivative proved to be 3A3 on the
PANC-1 cells (IC50 ¼ 0.114 mM) with lowest lipophilicity. The
results showed that the examined compounds exhibited
interesting optical as well as biological properties. Thus, this
can indicate their application as potential materials in
organic electronics as well as medicine, and this will be the
subject of our future investigations.
9 H. Hofmeier and U. S. Schubert, Chem. Soc. Rev., 2004, 33,
373–399.
¨
10 A. Mishra, E. Mena-Osteritz and P. Bauerle, Beilstein J. Org.
Chem., 2013, 9, 866–876.
11 S. S. M. Fernandes, M. Belsley, C. Ciarrocchi, M. Licchelli,
M. Manuela and M. Raposo, Dyes Pigm., 2018, 150, 49–58.
12 A. Baschieri, L. Sambri, I. Gualandi, D. Tonelli, F. Monti,
A. D. Esposti and N. Armaroli, RSC Adv., 2013, 3, 6507.
13 S. Zhang, Z. Xu, C. Gao, Q.-C. Ren, L. Chang, Z.-S. Lv and
L.-S. Feng, Eur. J. Med. Chem., 2017, 138, 501–513.
´
´
´
14 P. Lopez-Rojas, M. Janeczko, K. Kubinski, A. Amesty,
´
M. Masłyk and A. Estevez-Braun, Molecules, 2018, 23, 199.
15 M. H. Shaikh, D. D. Subhedar, L. Nawale, D. Sarkar,
F. A. Kalam Khan, J. N. Sangshetti and B. B. Shingate,
MedChemComm, 2015, 6, 1104–1116.
16 K. Wechakorn, S. Prabpai, K. Suksen, P. Kanjanasirirat,
Y. Pewkliang, S. Borwornpinyo and P. Kongsaeree,
Luminescence, 2018, 33, 64–70.
17 B. Rathinam, C.-C. Chien, B.-C. Chen and J.-H. Liu,
Tetrahedron, 2013, 69, 235–241.
18 H. C. Kolb and K. B. Sharpless, Drug Discovery Today, 2003, 8,
1128–1137.
19 M. S. Singh, S. Chowdhury and S. Koley, Tetrahedron, 2016,
72, 5257–5283.
Conflicts of interest
There are no conicts to declare.
This journal is © The Royal Society of Chemistry 2019
RSC Adv., 2019, 9, 16554–16564 | 16563